Siemens Healthineers Gets Varian In $16.4Bn Deal To Enter Cancer Treatment Market
China A Key Market As Highest Net Promoter for Varian
Executive Summary
In a bold move to expand into cancer treatment markets, Siemens Healthineers has agreed to a $16.4bn all-cash deal to acquire radiation therapy leader Varian.
You may also be interested in...
APACMed 2020: Healthineers Evolves Therapy Remit And Makes All Asia An Equal Priority
Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.
Dealmaking Quarterly Statistics, Q3 2020
During Q3 biopharmas reached $41.7bn in merger and acquisition value and drew in $44.4bn in potential deal value from alliances. Device company M&A values reached $17.9bn while in vitro diagnostic firms and research tools players completed M&A activity that totaled $8.2bn.
Industry Impact: Siemens Healthineers $16.4Bn Acquisition Of Varian – What Next?
Siemens Healthineers' acquisition of radiation oncology company Varian Medical Systems creates an oncology giant. Analysts disagree on whether its the right move for the companies.